Location and Time
March 22, 8:00 a.m. – 11:45 a.m. MDT
Four Seasons Ballroom
Karen E. Edison, MD, FAAD
Clarence S. Livingood, MD, Award and Lectureship
Leading Transformation in Dermatology Practice
The practice of dermatology continues to confront multiple forces that threaten to derail our mission to serve. As we have for over 100 years, we should own and take the lead in this transformation. Three key strategies to ensure we do so will be presented, including the creative use of technology, the power of full engagement, and the obligation to lead.
Suzanne L. Topalian, MD
Lila and Murray Gruber Memorial Cancer Research Award and Lectureship
Immune Checkpoint Blockade: A New Paradigm for Treating Melanoma and Other Skin Cancers
Just one decade ago, patients with advanced melanoma and other skin cancers had very few treatment options to extend survival. The recent development of a class of drugs known as “immune checkpoint blockers,” enabling the patient’s own immune system to attack cancer, has revolutionized treatment approaches in oncology. Building on this, new strategies are testing treatment combinations based on checkpoint inhibitors, and are examining a role for these therapies in earlier stages of skin cancer.
Aimee S. Payne, MD, PhD, FAAD
Eugene J. Van Scott Award for Innovative Therapy of the Skin and Philip Frost Lectureship Award
Taking Aim at Autoimmunity with CAAR T Cells
In 2017, the FDA approved groundbreaking anti-CD19 chimeric antigen receptor (CAAR) T-cell therapies that induce lasting remissions of B-cell cancers. Chimeric autoantibody receptor (CAAR) T-cells use the pemphigus autoantigen, DSG3, in an ex-vivo gene therapy to reprogram a patient’s T-cells to induce antigen-specific B-cell depletion. We will discuss the development path to support a proposed first-in-human trial to evaluate the safety and ability of DSG3 CAAR T-cells to induce durable remissions of autoimmunity in pemphigus.
John E. Harris, MD, PhD, FAAD
Marion B. Sulzberger, MD, Memorial Award and Lectureship
Vitiligo Treatment from the Iron Age to the Age of Biologics: New Hope for an Ancient Disease
Vitiligo was described 3,500 years ago in ancient Egyptian and Indian texts, and the social stigma associated with this disfiguring disease was evident from the very beginning. Forms of PUVA therapy were initiated during the Iron Age and rediscovered in the mid-20th century, yet within just the past 100 years patients were treated with either acid or arsenic. While these treatments have been replaced in modern times by safer options such as nbUVB and topical immunosuppressants, the search for even more effective, targeted therapies has continued. Research discoveries have inspired pathogenesis-directed treatments, such as Janus Kinase inhibitors, which have been effective in the first large clinical trials conducted for vitiligo. However, disease relapse is frequent when treatments are discontinued. New research shows promise for the development of better, longer-lasting treatments, and biologics to treat vitiligo are on the horizon. This Sulzberger Memorial Lecture will discuss the millennia-long search for better vitiligo treatments, including recent data that provides new hope for this ancient disease.
Dr. Larry Sabato is the professor of politics at the University of Virginia and the founder and head of the U.Va. Center for Politics, where his "Crystal Ball" electoral analysis expertly navigates the shifting sands of American electoral politics, accurately predicting the landslides, the nail-biters, and everything in between. Exclusively represented by Leading Authorities speakers bureau, Larry Sabato provides expert knowledge of what is coming down the pike, preparing us for the changing of the guard in Washington and across the nation. He bridges the gap between the rhetoric and the reality, showing audiences how the art of politics and the science of the American voting psyche come together to produce our nation’s next batch of leaders.
Back by popular demand… DermTales! Three winners were chosen to share a 5-minute story about an experience that had an impact on how they practice dermatology, or a time when they went above and beyond to make a difference for a patient or group of patients.
“Participating in DermTales was a unique opportunity to share a story that got to the heart of why I became a physician and a dermatologist. As much as I love research, at the end of the day, it's not a Kaplan-Meier curve that keeps me going; it's the patients. Being able to share my patient's story was an honor I'll never forget.”
─ Steven Chen, MD, MPH, FAAD, 2019 AAD Summer Meeting DermTales Speaker